Skip to content
Wenlo
Sign in
← Markets

Roivant Sciences Ltd.

Eric Venker (President & Immunovant CEO) sells ROIV shares

4ROIVFiled Nov 12, 2026, 7:00 PM ET· Period Nov 10, 2026

AI-generated summary

Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd., sold 187,943 common shares in open-market transactions on November 10, 2026, for a total value of $7,617,074.36 at an average price of $40.53. After the trades, the insider directly held 811,211 common shares. The sales were made under a Rule 10b5-1 trading plan adopted on June 30, 2026.

View original filing on SEC.gov (opens SEC EDGAR)

Key facts

Insider
Eric Venker · President & Immunovant CEO

Rule 10b5-1 plan · adopted Jun 30, 2026

DateTransactionSharesPriceValueHeld afterOwnership
Nov 10, 2026S · open-market saleFootnotes F1−158,194$40.44$6,397,365.36840,960Direct
Nov 10, 2026S · open-market saleFootnotes F2−29,749$41.00$1,219,709.00811,211Direct
Footnotes
  1. F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.92 to $40.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 30, 2026.
  2. F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.93 to $41.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 30, 2026.

More ROIV filings

Not investment advice. Summaries can contain errors; the SEC filing is the official record.